Longevity Biotech is developing new therapeutic drug candidates, which may have direct clinical impacts on patients lives. All of our programs are based on our Hybridtide peptide scaffold technology. Hybridtides are designed for long-acting oral administration.
Looking for a particular Longevity Biotech employee's phone or email?
The Longevity Biotech annual revenue was $1 million in 2026.
Scott Shandler is the Founder and CEO of Longevity Biotech.
2 people are employed at Longevity Biotech.
Longevity Biotech is based in Philadelphia, Pennsylvania.
The NAICS codes for Longevity Biotech are [5417, 541714, 54171, 54, 541].
The SIC codes for Longevity Biotech are [873, 87].